On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Beam Therapeutics Inc. disclosed that one patient died in the phase I/II trial testing BEAM-101 in sickle cell disease (SCD), though the case of respiratory failure was determined by the investigator ...

Acute myeloid leukemia was the most common reason for a transplant. Group 1 more commonly received myeloablative preparative ...

New approaches to cell transfer (or 'adoptive') therapy in patients involve lymphodepletion using non-myeloablative chemotherapy prior to autologous lymphocyte infusion. This approach can replace ...

Editas Medicine (EDIT) has been downgraded to market perform from outperform by Raymond James due in part to extended ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Raymond James downgraded Editas Medicine (EDIT) to Market Perform from Outperform without a price target The firm cites the company’s ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

Beam Therapeutics Inc (BEAM) reports encouraging clinical data for BEAM-101 in sickle cell treatment, while maintaining a ...

He is also working to reduce toxicities and maximize the cancer-killing powers of transplanted immune cells. One of Dr. Storb’s major scientific contributions is the non-myeloablative transplant.